TEL AVIV – Industrializing "luck" may open the door to a motherlode that the biopharmaceutical industry may be currently ignoring. One path to faster drug development, said Daphna Leifenfeld, is repurposing of existing drugs. This not only makes sense, but is something that the pharmaceutical industry should do more of, she said at the 17th Mixiii-Biomed Conference this week. The meeting in Israel is focused on trends shaping the future of health care systems and life sciences.